Screener
Collegium Pharmaceutical, Inc. COLL Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Collegium Pharmaceutical, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The source filing: Collegium Pharmaceutical, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 7:34 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053851
FAQ
- What is Collegium Pharmaceutical, Inc.'s cash & equivalents?
- Collegium Pharmaceutical, Inc. (COLL) reported cash & equivalents of $150.38M in Q2 2026.
- How has Collegium Pharmaceutical, Inc.'s cash & equivalents changed year-over-year?
- Collegium Pharmaceutical, Inc.'s cash & equivalents increased by 8.8% year-over-year, from $138.25M to $150.38M.
- What is the long-term trend for Collegium Pharmaceutical, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), Collegium Pharmaceutical, Inc.'s cash & equivalents has grown at a 7.7% compound annual growth rate (CAGR), from $174.12M to $252.16M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Collegium Pharmaceutical, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude